Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | FPR2 | P25090 | 2/20 | 0.32 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5372975 | 1.00 | POLB (0.35) | POLBALDH1A1GAACYP1A2CYP2D6 | |
| SCHEMBL5373017 | 0.82 | ALDH1A1 (0.34) | POLBALDH1A1GAACYP1A2CYP2D6 | |
| SCHEMBL5373012 | 0.82 | ALDH1A1 (0.34) | POLBALDH1A1GAACYP1A2CYP2D6 | |
| SCHEMBL764718 | 0.78 | ALDH1A1 (0.36) | POLBALDH1A1GAACYP1A2CYP2D6 | |
| SCHEMBL6294806 | 0.78 | POLB (0.33) | POLBALDH1A1GAACYP1A2CYP2D6 | |
| SCHEMBL5369754 | 0.73 | ALDH1A1 (0.44) | ALDH1A1GAACYP1A2CYP2D6NPC1 | |
| SCHEMBL5369758 | 0.73 | ALDH1A1 (0.44) | ALDH1A1GAACYP1A2CYP2D6NPC1 | |
| SCHEMBL5381056 | 0.71 | ALDH1A1 (0.42) | ALDH1A1GAACYP1A2CYP2D6NPC1 | |
| SCHEMBL5381060 | 0.71 | ALDH1A1 (0.42) | ALDH1A1GAACYP1A2CYP2D6NPC1 | |
| SCHEMBL9429829 | 0.71 | POLB (0.36) | POLBALDH1A1CYP1A2NPC1FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100355735-C | Method for preparing arylalkyne | BAYER CHEMICAL PRODUCT AG (DE) | 2007-12-19 | — | — | CN | claimed |
| US-20040192952-A1 | Process for preparing arylalkynes | LANXESS DEUTSCHLAND GMBH (DE) | 2004-09-30 | — | — | US | claimed |
| CN-1517340-A | Method for preparing arylalkyne | ˹���ػ�ѧ��Ʒ�ɷ�����˾ | 2004-08-04 | — | — | CN | claimed |
| US-20040142820-A1 | Pyrazolylarylalkines | VENTURE LENDING & LEASING IX, INC. | 2004-07-22 | — | — | US | claimed |
| EP-1437347-A2 | PROCESS FOR THE PREPARATION OF ARYLVINYL HALIDES AND ARALKINYL COMPOUNDS | Bayer Chemicals AG (DE) | 2004-07-14 | — | — | EP | claimed |
| CN-100528845-C | Pyrazolyl arync | BAYER CHEMICAL PRODUCT AG (DE) | 2009-08-19 | — | — | CN | disclosed |
| US-7312350-B2 | Process for preparing arylalkynes | LANXESS DEUTSCHLAND GMBH (DE) | 2007-12-25 | — | — | US | disclosed |
| CN-100355735-C | Method for preparing arylalkyne | BAYER CHEMICAL PRODUCT AG (DE) | 2007-12-19 | — | — | CN | disclosed |
| US-6916839-B2 | Pyrazolylarylalkines | BAYER CHEMICALS AKTIENGESELLSCHAFT (DE) | 2005-07-12 | — | — | US | disclosed |
| US-20040192952-A1 | Process for preparing arylalkynes | LANXESS DEUTSCHLAND GMBH (DE) | 2004-09-30 | — | — | US | disclosed |
| CN-1517340-A | Method for preparing arylalkyne | ˹���ػ�ѧ��Ʒ�ɷ�����˾ | 2004-08-04 | — | — | CN | disclosed |
| CN-1517339-A | Pyrazolyl arync | 拜尔化学品股份公司 | 2004-08-04 | — | — | CN | disclosed |
| US-20040142820-A1 | Pyrazolylarylalkines | VENTURE LENDING & LEASING IX, INC. | 2004-07-22 | — | — | US | disclosed |
| EP-1437347-A2 | PROCESS FOR THE PREPARATION OF ARYLVINYL HALIDES AND ARALKINYL COMPOUNDS | Bayer Chemicals AG (DE) | 2004-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192952-A1 | Process for preparing arylalkynes | ARSA, STS, HDHD5 | POLB 746/4885ALDH1A1 380/4885GAA 2162/4885 |
| US-20040142820-A1 | Pyrazolylarylalkines | CBR3, PPOX, ALK | POLB 951/4885ALDH1A1 603/4885GAA 2512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.